Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries
ConclusionThe availability of biosimilars was associated with a decrease in adalimumab expenditure without compromising the consumption of adalimumab.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
More News: African Health | Australia Health | Austria Health | Brazil Health | Canada Health | Drugs & Pharmacology | France Health | Germany Health | Humira | Italy Health | Japan Health | Singapore Health | South Africa Health | Spain Health | Study | Sweden Health | Taiwan Health | USA Health